# US 12,594,251 B2 · Benzalkonium chloride foruse in treating conjunctivitis and/or covid-19

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,594,251 B2
- Document ID: US12594251B2
- Status: Granted
- Kind: B2
- Application number: 18/248,841
- Filed: 2021-10-14
- Published: 2023-12-07
- Granted: 2026-04-07
- Earliest claimed: 2020-10-15
- Assignees: Bausch + Lomb Ireland Limited
- Applicants: Bausch + Lomb Ireland Limited
- Inventors: Patrick McCormick; Kimberly Millard
- Web page: https://patentgrep.com/patent/US12594251B2

## CPC

- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/4402: only substituted in position 2, e.g. pheniramine, bisacodyl
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61P 27/02: Ophthalmic agents
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods for treating coronavirus disease 2019 (COVID-19), including at least one ocular manifestation of COVID-19, methods for treating conjunctivitis, and methods for reducing COVID-19 transmission comprising administering an effective amount of benzalkonium chloride are disclosed. Pharmaceutical compositions comprising benzalkonium chloride are also disclosed.

## Claims

### Claim 1

A method for treating at least one ocular manifestation of coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.

### Claim 3 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.

### Claim 4 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.

### Claim 5 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is topically administered.

### Claim 6 (depends on 1)

The method of claim 1, wherein the pharmaceutical composition is administered to at least one eye of the subject.

### Claim 7 (depends on 1)

The method of claim 1, wherein treating at least one ocular manifestation of COVID-19 comprises treating at least one disease or condition chosen from eye redness, conjunctivitis, keratoconjunctivitis, dry eye disease, blurred vision, conjunctival hyperaemia, ocular irritation, foreign body sensation, epiphora, eyelid edema, and chemosis.

### Claim 8 (depends on 1)

The method of claim 1, wherein treating at least one ocular manifestation of COVID-19 comprises treating conjunctivitis.

### Claim 9 (depends on 1)

The method of claim 1, wherein treating at least one ocular manifestation of COVID-19 comprises improving visual acuity.

### Claim 10 (depends on 1)

The method of claim 1, wherein treating at least one ocular manifestation of COVID-19 comprises reducing eye redness, ocular irritation, or foreign body sensation.

### Claim 11

A method for reducing a risk of SARS-COV-2 ocular transmission comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.

### Claim 12 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.

### Claim 13 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.

### Claim 14 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.

### Claim 15 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition is topically administered.

### Claim 16 (depends on 11)

The method of claim 11, wherein the pharmaceutical composition is administered to at least one eye of the subject.

### Claim 17

A method for preventing coronavirus disease 2019 (COVID-19) comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.

### Claim 18 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.

### Claim 19 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.

### Claim 20 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.

### Claim 21 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition is topically administered.

### Claim 22 (depends on 17)

The method of claim 17, wherein the pharmaceutical composition is administered to at least one eye of the subject.

### Claim 23

A method for reducing an ocular SARS-COV-2 viral load comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.

### Claim 24 (depends on 23)

The method of claim 23, wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.02% (w/v) benzalkonium chloride.

### Claim 25 (depends on 23)

The method of claim 23, wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.

### Claim 26 (depends on 23)

The method of claim 23, wherein the pharmaceutical composition is the form of an eye drop, a suspension, a gel, an ointment, an injectable solution, or a spray.

### Claim 27 (depends on 23)

The method of claim 23, wherein the pharmaceutical composition is topically administered.

### Claim 28 (depends on 23)

The method of claim 23, wherein the pharmaceutical composition is administered to at least one eye of the subject.

### Claim 29

A method for reducing an intranasal SARS-COV-2 viral load comprising administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.

### Claim 30 (depends on 29)

The method of claim 29, wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.2% (w/v) benzalkonium chloride.

### Claim 31 (depends on 29)

The method of claim 29, wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.2% (w/v) benzalkonium chloride.

### Claim 32 (depends on 29)

The method of claim 29, wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.1% (w/v) benzalkonium chloride.

### Claim 33 (depends on 29)

The method of claim 29, wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.

### Claim 34

The method of 29, wherein the pharmaceutical composition is the form of a spray.

### Claim 35

A method for treating or preventing coronavirus disease 2019 (COVID-19) comprising intranasally administering to a subject in need thereof a pharmaceutical composition comprising an effective amount of benzalkonium chloride, pheniramine maleate, and naphazoline HCl.

### Claim 36 (depends on 35)

The method of claim 35, wherein the pharmaceutical composition comprises 0.001% (w/v) to 0.2% (w/v) benzalkonium chloride.

### Claim 37 (depends on 35)

The method of claim 35, wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.2% (w/v) benzalkonium chloride.

### Claim 38 (depends on 35)

The method of claim 35, wherein the pharmaceutical composition comprises 0.005% (w/v) to 0.1% (w/v) benzalkonium chloride.

### Claim 39 (depends on 35)

The method of claim 35, wherein the pharmaceutical composition comprises 0.01% (w/v) benzalkonium chloride.

### Claim 40 (depends on 35)

The method of claim 35, wherein the pharmaceutical composition is the form of a spray.